• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

The following list of names for the drugs described are "under consideration" by the USAN Council:

March 2014

firocaftor treatment of cystic fibrosis
ravadasvir treatment of hepatitis C

February 2014

relebactam antibacterial
sevatinib tyrosine kinase inhibitor

January 2014

abrelizumab treatment of lupus
aquecumab antineoplastic
bemaciclib treatment of advanced cancer
brigatinib antineoplastic
ferric citrate control of serum phosphorus levels
lanopepden antibacterial
luberecumab antineoplastic
merestinib antineoplastic
olanespib treatment of cancer
olterotinib antineoplastic
pegpleranib sodium treatment of age-related macular degeneration (AMD)
relanepag treatment of pulmonary arterial hypertension
relebactam antibacterial
solcitinib treatment of immunological disorders
susaquetide reduce intensity and duration of tissue damage caused by inflammation cascade and mucositis, increase clearance of bacterial infection
toreforant treatment of rheumatoid arthritis and asthma
verubecestat treatment of Alzheimer's disease